Thilagesh P.

Thilagesh P.

Auto-generated profile, based on publicly available information

Thilagesh P.

Sri Shanmugha College of Pharmacy Department of Pharmacy Practice Salem India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
TPThilagesh P.
Thilagesh P.
ASAnand Kumar S.
Anand Kumar S.
AUAiswarya Nair U.
Aiswarya Nair U.
RSRabiniraj S.
Rabiniraj S.
SPShobana P.
Shobana P.
SKSriram K.
Sriram K.
1: Liver metastases from Gastrointestinal (GI) cancers present significant challenges in oncology, often signaling poor prognosis. Traditional detection methods like imaging and tissue biopsies have limitations in sensitivity, specificity, and tumor heterogeneity representation. The advent of artificial intelligence (AI) in healthcare, driven by advancements in machine learning, algorithms, and data science, offers a promising frontier for early detection and management of liver metastases. This review explores the integration of AI and liquid biopsy technologies as transformative tools in the proactive detection of liver metastases arising from GI malignancies. : Liquid biopsy, a non-invasive method, analyzes circulating tumor cells (CTCs), cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA) in bodily fluids. It provides a comprehensive overview of tumor heterogeneity and enables real-time monitoring of tumor evolution and treatment response. Despite its advantages, liquid biopsy faces challenges such as low sensitivity for early-stage metastases, reduced detectability due to liver filtration, and technical limitations. : AI enhances the potential of liquid biopsies by improving diagnostic accuracy through advanced algorithms like Convolutional Neural Networks (CNNs) and Natural Language Processing (NLP). These AI models analyze complex biomedical data, offering higher sensitivity and specificity in cancer detection. The synergy between AI and liquid biopsies promises early detection, better disease monitoring, and personalized treatment strategies. : This review underscores the significant advancements AI and liquid biopsy technologies bring to oncological precision medicine, particularly in improving overall survival (OS) and disease-free survival (DFS) for patients with GI cancer metastases. As we transition into the era of precision medicine, the integration of these technologies holds the potential to redefine cancer care and patient management.

27 March 2026 in Current Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Closed access
TPThilagesh P
Thilagesh P
AUAiswarya Nair U
Aiswarya Nair U
ASAnand Kumar S
Anand Kumar S
AKAkshaya Krishnan
Akshaya Krishnan
GSGokilavani S
Gokilavani S
SMShankar Ganesh M
Shankar Ganesh M
Introduction/Objective: Thiopurines (azathioprine, 6-mercaptopurine) are pivotal for IBD remission induction but possess a narrow therapeutic index and large PK/PD variability. We assess integrating TPMT and NUDT15 genotyping with pharmacometric models to support genotype-directed, model-informed precision dosing beyond empiric approaches and traditional therapeutic drug monitoring. Methods: We performed a narrative review of pharmacometric and pharmacogenetic research, evaluating (i) genotype–phenotype correlation for TPMT and NUDT15 by ancestry; (ii) population PK/PD and Bayesian or nonlinear mixed-effects modeling with genetic, biochemical, and co-medication covariates; and (iii) biomarker approaches comparing red-cell 6-thioguanine nucleotide assays vs. DNA-thioguanine, and clinical outcomes. Results: NUDT15 R139C alleles impart high early-onset leukopenic risk at nominal doses, particularly in East/South Asians, challenging genotype-blind dosing and conventional 6-TGN–based monitoring. TPMT polymorphisms, despite their traditional prominence, exhibit genotype–phenotype discordance and diminished predictive value outside of primarily Caucasian populations. Bayesian and mixed-effects models of the present day provide individualized dosing in real time; however, widely generalizable, genotype-normalized PK/PD paradigms and routine inclusion of higher-resolution biomarkers like DNA-TG are limited. Discussion: Dependence on historic TDM and TPMT-favoring strategies is inadequate in heterogeneous populations and for NUDT15 variant-associated early toxicity. Incorporation of diplotype-directed MIPD with solid PK/PD modeling and improved biomarkers may change thiopurine treatment from dose-measure-reactive to dose-predictive. Challenges involve ancestry-sensitive algorithms, standardized DNA-TG assays, and EHR-based, validated decision support. Conclusion MIPD combining TPMT/NUDT15 diplotypes, adaptive PK/PD modeling, and high-resolution biomarkers can make thiopurine treatment in IBD a modernized reality. Widespread implementation necessitates ancestry-adapted, clinically established algorithms, decision support, and multicenter testing to provide safe, effective, and equitable dosing.

2 October 2026 in Current Respiratory Medicine Reviews
Verified
Journal Article
Closed access
PDF file
SKSriram K
Sriram K
PVPrabhakar V
Prabhakar V
PNPreethi N
Preethi N
VRVijayakumar Ramakrishnan
Vijayakumar Ramakrishnan
TPThilagesh P
Thilagesh P
SMShankar Ganesh M
Shankar Ganesh M
Introduction: Pulmonary tuberculosis (PTB) and nontuberculous mycobacterial pulmonary disease (NTM-PD) often require prolonged multidrug therapy because phenotypically tolerant and persistent bacilli survive within heterogeneous pulmonary niches despite genetic susceptibility. This review evaluates mechanisms underlying these non-heritable survival states and therapeutic strategies that may improve sterilizing cure. Methods: Literature from 2000 to March 2026 was searched in PubMed/MEDLINE, ScienceDirect, Embase, Scopus, Web of Science, and ClinicalTrials.gov. Mechanistic, translational, pharmacological, clinical, and guideline studies addressing dormancy, biofilms, intracellular persistence, lesion pharmacology, efflux, metabolic adaptation, host-directed therapy, and pulmonary drug delivery were narratively synthesized. Results: Hypoxic, acidic, nutrient-limited, lipid-rich caseous, intracellular, and mucus/biofilmassociated environments create spatial and metabolic heterogeneity that slows bacillary killing without necessarily increasing the minimum inhibitory concentration. Persistence is sustained by DosRlinked adaptation, respiratory and ATP dependence, altered envelope permeability, adaptive efflux, macrophage conditioning, and biofilm architecture. Persister-active combinations, respiratory-chain inhibition, biofilm disruption, host-directed adjuncts, inhaled/liposomal delivery, and lesionpenetrant optimization are the most promising approaches. Discussion: Current susceptibility testing and plasma-based exposure measures incompletely represent protected pulmonary compartments, and validated clinical biomarkers of persister burden remain limited. Future trials should prioritize compartment-aware pharmacology and relapse-free sterilization endpoints. Conclusion: Durable cure will likely require combining susceptibility-guided therapy with strategies that eradicate phenotypically tolerant bacilli across pulmonary niches.